person · Reporting owner

Scott Randal W.

Disclosed activity across 4 companies

Tapewire entity: 28579
SEC CIK: 0001337801

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BridgeBio Pharma, Inc.BBIO · Entity 3360	Director	May 15, 2026	May 19, 2026
Freenome, Inc.FRNM · Entity 4644	Director	July 20, 2026	July 28, 2026
Invitae CorpNVTA · Entity 95935	Director	April 27, 2023	May 01, 2023
Talis Biomedical CorpTLIS · Entity 87664	Director	June 09, 2023	June 12, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BridgeBio Pharma, Inc.

Report date May 15, 2026 · Filed May 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,589	Ending reported balance After 2026-05-15 transaction · row 5 5 source rows · reconciled sequence Row 1 · 2026-05-15 · Exercise / conversion · Acquired 10,000 · Balance 21,589 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. Row 2 · 2026-05-15 · Sale · Disposed 6,200 · Balance 15,389 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F2: Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Row 3 · 2026-05-15 · Sale · Disposed 2,088 · Balance 13,301 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F3: Represents the weighted average sale price of the shares sold from $67.10 to $68.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Row 4 · 2026-05-15 · Sale · Disposed 1,512 · Balance 11,789 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F4: Represents the weighted average sale price of the shares sold from $68.10 to $68.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Row 5 · 2026-05-15 · Sale · Disposed 200 · Balance 11,589 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.75 · Expires 2033-06-21	Direct	21,501	Reported balance After 2026-05-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-15 · Exercise / conversion · Disposed 10,000 · Balance 21,501 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F5: One-third of the shares underlying the option will vest on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Common StockSEC Table I · non-derivative	IndirectBy Thinking Bench Capital LLC	4,000	Reported balance Holding disclosure · report date 2026-05-15 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 4,000

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025.

F2: Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3: Represents the weighted average sale price of the shares sold from $67.10 to $68.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F4: Represents the weighted average sale price of the shares sold from $68.10 to $68.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F5: One-third of the shares underlying the option will vest on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Freenome, Inc.

Report date July 20, 2026 · Filed July 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,235	Reported balance Holding disclosure · report date 2026-07-20 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 12,235
Common StockSEC Table I · non-derivative	IndirectBy Thinking Bench Capital, LLC	91,969	Reported balance Holding disclosure · report date 2026-07-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 91,969 F1: Represents shares held by Thinking Bench Capital, LLC. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2028-07-25	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-20 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: The shares subject to this option are fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.91 · Expires 2032-04-26	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-20 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F5: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F2: The shares subject to this option are fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.91 · Expires 2032-06-27	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-20 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F5: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F2: The shares subject to this option are fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.92 · Expires 2033-09-10	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-20 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F5: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F3: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 28, 2023, subject to the Reporting Person's continued service on each such vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.24 · Expires 2034-03-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-20 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed F5: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F4: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 2, 2024, subject to the Reporting Person's continued service on each such vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-05-28	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-20 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance Not disclosed F5: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F2: The shares subject to this option are fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2035-10-23	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-20 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance Not disclosed F2: The shares subject to this option are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares held by Thinking Bench Capital, LLC. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F2: The shares subject to this option are fully vested.

F3: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 28, 2023, subject to the Reporting Person's continued service on each such vesting date.

F4: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 2, 2024, subject to the Reporting Person's continued service on each such vesting date.

F5: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events.

Invitae Corp

Report date April 27, 2023 · Filed May 01, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	161,222	Reported balance After 2023-04-27 transaction · row 1 1 source row Row 1 · 2023-04-27 · Grant · Acquired 70,422 · Balance 161,222 F1: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2024, subject to continued service with the Issuer through the vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2033-04-27	Direct	28,901	Reported balance After 2023-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-04-27 · Grant · Acquired 28,901 · Balance 28,901 F2: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2033-04-27	Direct	86,705	Reported balance After 2023-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-04-27 · Grant · Acquired 86,705 · Balance 86,705 F3: Represents Board Chair Compensation. F2: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates.
Common StockSEC Table I · non-derivative	IndirectBy OG Family Trust	60,000	Reported balance Holding disclosure · report date 2023-04-27 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 60,000

Filing footnotes · ownership attribution and instrument terms

F1: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2024, subject to continued service with the Issuer through the vesting date.

F2: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates.

F3: Represents Board Chair Compensation.

Talis Biomedical Corp

Report date June 09, 2023 · Filed June 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-09	Direct	95,000	Reported balance After 2023-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-09 · Grant · Acquired 95,000 · Balance 95,000 F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 15, 2026 Filed May 19, 2026 20:25 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $16.75	$0.00	Disclosure SEC source: 0001470831-26-000470 · wk-form4_1779222325.xml · derivative · entry 7 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,501 Underlying: Common Stock · 10,000 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F5 · derivative.exercise_date: One-third of the shares underlying the option will vest on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
May 15, 2026 Filed May 19, 2026 20:25 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	200	$69.12	$13,824.00	Disclosure SEC source: 0001470831-26-000470 · wk-form4_1779222325.xml · nonDerivative · entry 5 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,589 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. Read SEC document
May 15, 2026 Filed May 19, 2026 20:25 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	1,512	$68.23	$103,164.21	Disclosure SEC source: 0001470831-26-000470 · wk-form4_1779222325.xml · nonDerivative · entry 4 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,789 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $68.10 to $68.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
May 15, 2026 Filed May 19, 2026 20:25 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	2,088	$67.53	$141,003.06	Disclosure SEC source: 0001470831-26-000470 · wk-form4_1779222325.xml · nonDerivative · entry 3 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,301 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $67.10 to $68.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
May 15, 2026 Filed May 19, 2026 20:25 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	6,200	$66.69	$413,464.36	Disclosure SEC source: 0001470831-26-000470 · wk-form4_1779222325.xml · nonDerivative · entry 2 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,389 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
May 15, 2026 Filed May 19, 2026 20:25 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	10,000	$16.75	$167,500.00	Disclosure SEC source: 0001470831-26-000470 · wk-form4_1779222325.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. Read SEC document
February 17, 2026 Filed Feb 18, 2026 23:34 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $16.75	$0.00	Disclosure SEC source: 0001470831-26-000182 · wk-form4_1771457650.xml · derivative · entry 6 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,501 Underlying: Common Stock · 10,000 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
February 17, 2026 Filed Feb 18, 2026 23:34 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	3,307	$75.93	$251,087.61	Disclosure SEC source: 0001470831-26-000182 · wk-form4_1771457650.xml · nonDerivative · entry 4 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,589 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $75.82 to $76.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
February 17, 2026 Filed Feb 18, 2026 23:34 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	4,793	$75.57	$362,218.99	Disclosure SEC source: 0001470831-26-000182 · wk-form4_1771457650.xml · nonDerivative · entry 3 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,896 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $74.82 to $75.815 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
February 17, 2026 Filed Feb 18, 2026 23:34 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	1,900	$74.34	$141,249.99	Disclosure SEC source: 0001470831-26-000182 · wk-form4_1771457650.xml · nonDerivative · entry 2 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,689 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $73.74 to $74.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
February 17, 2026 Filed Feb 18, 2026 23:34 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	10,000	$16.75	$167,500.00	Disclosure SEC source: 0001470831-26-000182 · wk-form4_1771457650.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:06 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $16.75	$0.00	Disclosure SEC source: 0001470831-25-000355 · wk-form4_1763590009.xml · derivative · entry 5 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,501 Underlying: Common Stock · 10,000 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F4 · derivative.exercise_date: One-third of the shares underlying the option vested on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:06 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	6,199	$66.89	$414,656.07	Disclosure SEC source: 0001470831-25-000355 · wk-form4_1763590009.xml · nonDerivative · entry 3 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,589 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $66.65 to $67.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:06 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	3,801	$66.25	$251,809.03	Disclosure SEC source: 0001470831-25-000355 · wk-form4_1763590009.xml · nonDerivative · entry 2 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,788 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $65.64 to $66.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:06 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	10,000	$16.75	$167,500.00	Disclosure SEC source: 0001470831-25-000355 · wk-form4_1763590009.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:54 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	8,425	$0.00 Strike: $41.73	$0.00	Disclosure SEC source: 0000950170-25-089642 · ownership.xml · derivative · entry 3 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:54 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantCommon Stock	6,589	$0.00	$0.00	Disclosure SEC source: 0000950170-25-089642 · ownership.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,589 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 21, 2024 Filed Jun 25, 2024 21:42 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	26,014	$0.00 Strike: $27.36	$0.00	Disclosure SEC source: 0000950170-24-077452 · ownership.xml · derivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document
June 04, 2024 Filed Jun 5, 2024 20:53 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	1,500	$31.30	$46,950.00	Disclosure SEC source: 0000950170-24-069401 · ownership.xml · nonDerivative · entry 3 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Thinking Bench Capital LLC Disclosed balance after: 4,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. Read SEC document
June 03, 2024 Filed Jun 5, 2024 20:53 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	200	$29.48	$5,895.00	Disclosure SEC source: 0000950170-24-069401 · ownership.xml · nonDerivative · entry 2 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Thinking Bench Capital LLC Disclosed balance after: 5,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. F3 · price: Represents the weighted average sale price of the shares sold ranging from $29.44 to $29.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
June 03, 2024 Filed Jun 5, 2024 20:53 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	800	$28.68	$22,947.52	Disclosure SEC source: 0000950170-24-069401 · ownership.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Thinking Bench Capital LLC Disclosed balance after: 5,700 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. F2 · price: Represents the weighted average sale price of the shares sold ranging from $28.31 to $29.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:00 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	2,500	$34.00	$85,000.00	Disclosure SEC source: 0000950170-24-025839 · ownership.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Thinking Bench Capital LLC Disclosed balance after: 6,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. Read SEC document
December 18, 2023 Filed Dec 20, 2023 21:00 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	2,000	$40.00	$80,000.00	Disclosure SEC source: 0001209191-23-059324 · doc4.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 9,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. F2 · ownership.nature: By Thinking Bench Capital LLC. Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:00 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	1,500	$30.00	$45,000.00	Disclosure SEC source: 0001209191-23-057374 · doc4.xml · nonDerivative · entry 2 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 11,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. F2 · ownership.nature: By Thinking Bench Capital LLC. Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:00 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	1,000	$28.50	$28,500.00	Disclosure SEC source: 0001209191-23-057374 · doc4.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 12,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. F2 · ownership.nature: By Thinking Bench Capital LLC. Read SEC document
September 05, 2023 Filed Sep 7, 2023 20:00 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	2,500	$30.00	$75,000.00	Disclosure SEC source: 0001209191-23-048595 · doc4.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 13,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. F2 · ownership.nature: By Thinking Bench Capital LLC. Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:24 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	51,501	$0.00 Strike: $16.75	$0.00	Disclosure SEC source: 0001209191-23-039393 · doc4.xml · derivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
June 09, 2023 Filed Jun 12, 2023 21:29 UTC	Talis Biomedical Corp TLIS · Entity 87664	GrantStock option (right to buy) · Derivative	95,000	$0.00 Strike: $0.50	$0.00	Disclosure SEC source: 0001209191-23-036409 · doc4.xml · derivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2033-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date. Read SEC document
April 27, 2023 Filed May 1, 2023 20:20 UTC	Invitae Corp NVTA · Entity 95935	GrantStock Option (right to buy) · Derivative	86,705	$0.00 Strike: $1.36	$0.00	Disclosure SEC source: 0000899243-23-011937 · doc4.xml · derivative · entry 4 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,705 Underlying: Common Stock · 86,705 shares Expires 2033-04-27 F3 · shares: Represents Board Chair Compensation. F2 · derivative.exercise_date: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates. Read SEC document
April 27, 2023 Filed May 1, 2023 20:20 UTC	Invitae Corp NVTA · Entity 95935	GrantStock Option (right to buy) · Derivative	28,901	$0.00 Strike: $1.36	$0.00	Disclosure SEC source: 0000899243-23-011937 · doc4.xml · derivative · entry 3 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,901 Underlying: Common Stock · 28,901 shares Expires 2033-04-27 F2 · derivative.exercise_date: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates. Read SEC document
April 27, 2023 Filed May 1, 2023 20:20 UTC	Invitae Corp NVTA · Entity 95935	GrantCommon Stock	70,422	$0.00	$0.00	Disclosure SEC source: 0000899243-23-011937 · doc4.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,222 F1 · shares: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2024, subject to continued service with the Issuer through the vesting date. Read SEC document
July 16, 2022 Filed Jul 19, 2022 22:48 UTC	Invitae Corp NVTA · Entity 95935	GrantEmployee Stock Option (right to buy) · Derivative	4,275	$0.00 Strike: $2.85	$0.00	Disclosure SEC source: 0000899243-22-026378 · doc4.xml · derivative · entry 5 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,275 Underlying: Common Stock · 4,275 shares Expires 2032-07-16 F4 · derivative.exercise_date: Option vests in nine equal monthly installments starting from July 16, 2022. Read SEC document
July 16, 2022 Filed Jul 19, 2022 22:48 UTC	Invitae Corp NVTA · Entity 95935	GrantEmployee Stock Option (right to buy) · Derivative	22,730	$0.00 Strike: $2.85	$0.00	Disclosure SEC source: 0000899243-22-026378 · doc4.xml · derivative · entry 4 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,730 Underlying: Common Stock · 22,730 shares Expires 2032-07-16 F3 · derivative.exercise_date: Option vests over four years, with 25% of the shares vesting on July 16, 2023, and 1/48th of the remaining shares vesting monthly thereafter for the remaining three years. Read SEC document
July 16, 2022 Filed Jul 19, 2022 22:48 UTC	Invitae Corp NVTA · Entity 95935	GrantCommon Stock	8,475	$0.00	$0.00	Disclosure SEC source: 0000899243-22-026378 · doc4.xml · nonDerivative · entry 2 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,800 F2 · shares: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2023. Read SEC document
July 16, 2022 Filed Jul 19, 2022 22:48 UTC	Invitae Corp NVTA · Entity 95935	GrantCommon Stock	45,325	$0.00	$0.00	Disclosure SEC source: 0000899243-22-026378 · doc4.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,325 F1 · shares: Shares issuable upon settlement of a restricted stock unit award that vests in four equal installments, with 1/4th of the total award vesting on each of August 15, 2023, 2024, 2025 and 2026, subject to continued service with the issuer through the applicable vesting dates. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:37 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	104,921	$0.00 Strike: $8.45	$0.00	Disclosure SEC source: 0001209191-22-039268 · doc4.xml · derivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
June 10, 2022 Filed Jun 13, 2022 21:41 UTC	Talis Biomedical Corp TLIS · Entity 87664	GrantStock Option (right to buy) · Derivative	95,000	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0001209191-22-036427 · doc4.xml · derivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date. Read SEC document
June 17, 2021 Filed Jun 22, 2021 22:47 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	38,895	$0.00 Strike: $62.63	$0.00	Disclosure SEC source: 0000899243-21-025362 · doc4.xml · derivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,895 Underlying: Common Stock · 38,895 shares Expires 2031-06-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document
May 17, 2021 Filed May 18, 2021 19:19 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon stock	11,000	$10.11	$111,210.00	Disclosure SEC source: 0001209191-21-033441 · doc4.xml · nonDerivative · entry 2 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F2 · price: This purchase was executed in multiple purchases at prices ranging from $10.00 to $10.15. The price reported above reflects the weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 14, 2021 Filed May 18, 2021 19:19 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon stock	9,000	$10.16	$91,440.00	Disclosure SEC source: 0001209191-21-033441 · doc4.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · price: This purchase was executed in multiple purchases at prices ranging from $10.03 to $10.25. The price reported above reflects the weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 17, 2021 Filed Feb 18, 2021 23:21 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	PurchaseCommon Stock	16,000	$62.50	$1,000,000.00	Disclosure SEC source: 0000899243-21-007172 · doc4.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:18 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionSeries F-1 Preferred Stock · Derivative	432,749	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012519 · doc4.xml · derivative · entry 7 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Thinking Bench Capital, LLC Disclosed balance after: 0 Underlying: Common Stock · 302,621 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock. F4 · derivative.exercise_date: Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock. F4 · derivative.expiration_date: Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock. F2 · ownership.nature: The shares are held by Thinking Bench Capital, LLC, for which Dr. Scott is the manager. The OG Family Trust, u/d/t May 30, 2014 is the sole member of Thinking Bench Capital, LLC. Dr. Scott and his spouse are trustees and share voting and dispositive power of the OG Family Trust, u/d/t May 30, 2014. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:18 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionSeries E-1 Preferred Stock · Derivative	478,402	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012519 · doc4.xml · derivative · entry 6 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Thinking Bench Capital, LLC Disclosed balance after: 0 Underlying: Common Stock · 334,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F3 · derivative.exercise_date: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F3 · derivative.expiration_date: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F2 · ownership.nature: The shares are held by Thinking Bench Capital, LLC, for which Dr. Scott is the manager. The OG Family Trust, u/d/t May 30, 2014 is the sole member of Thinking Bench Capital, LLC. Dr. Scott and his spouse are trustees and share voting and dispositive power of the OG Family Trust, u/d/t May 30, 2014. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:18 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionSeries D-1 Preferred Stock · Derivative	1,076,643	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012519 · doc4.xml · derivative · entry 5 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Thinking Bench Capital, LLC Disclosed balance after: 0 Underlying: Common Stock · 752,897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series D-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series D-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series D-1 Preferred Stock. F1 · derivative.exercise_date: Each share of Series D-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series D-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series D-1 Preferred Stock. F1 · derivative.expiration_date: Each share of Series D-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series D-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series D-1 Preferred Stock. F2 · ownership.nature: The shares are held by Thinking Bench Capital, LLC, for which Dr. Scott is the manager. The OG Family Trust, u/d/t May 30, 2014 is the sole member of Thinking Bench Capital, LLC. Dr. Scott and his spouse are trustees and share voting and dispositive power of the OG Family Trust, u/d/t May 30, 2014. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:18 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon Stock	312,500	$16.00	$5,000,000.00	Disclosure SEC source: 0001209191-21-012519 · doc4.xml · nonDerivative · entry 4 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By OG Family Trust, u/d/t May 30, 2014 Disclosed balance after: 312,500 F5 · ownership.nature: The shares are held directly by the OG Family Trust, u/d/t May 30, 2014. Dr. Scott and his spouse are trustees and share voting and dispositive power over the shares held by OG Family Trust, u/d/t May 30, 2014. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:18 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionCommon Stock	302,621	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012519 · doc4.xml · nonDerivative · entry 3 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Thinking Bench Capital, LLC Disclosed balance after: 1,390,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock. F2 · ownership.nature: The shares are held by Thinking Bench Capital, LLC, for which Dr. Scott is the manager. The OG Family Trust, u/d/t May 30, 2014 is the sole member of Thinking Bench Capital, LLC. Dr. Scott and his spouse are trustees and share voting and dispositive power of the OG Family Trust, u/d/t May 30, 2014. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:18 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionCommon Stock	334,546	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012519 · doc4.xml · nonDerivative · entry 2 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Thinking Bench Capital, LLC Disclosed balance after: 1,087,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F2 · ownership.nature: The shares are held by Thinking Bench Capital, LLC, for which Dr. Scott is the manager. The OG Family Trust, u/d/t May 30, 2014 is the sole member of Thinking Bench Capital, LLC. Dr. Scott and his spouse are trustees and share voting and dispositive power of the OG Family Trust, u/d/t May 30, 2014. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:18 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionCommon Stock	752,897	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012519 · doc4.xml · nonDerivative · entry 1 Scott Randal W. · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Thinking Bench Capital, LLC Disclosed balance after: 752,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series D-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series D-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series D-1 Preferred Stock. F2 · ownership.nature: The shares are held by Thinking Bench Capital, LLC, for which Dr. Scott is the manager. The OG Family Trust, u/d/t May 30, 2014 is the sole member of Thinking Bench Capital, LLC. Dr. Scott and his spouse are trustees and share voting and dispositive power of the OG Family Trust, u/d/t May 30, 2014. Read SEC document
June 23, 2020 Filed Jun 25, 2020 20:41 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	101,223	$0.00 Strike: $32.62	$0.00	Disclosure SEC source: 0000899243-20-017667 · doc4.xml · derivative · entry 1 Scott Randal W · CIK 0001337801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,223 Underlying: Common Stock · 101,223 shares Expires 2030-06-22 F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in three annual installments after June 23, 2020, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
August 26, 2019 Filed Aug 27, 2019 23:18 UTC	Invitae Corp NVTA · Entity 95935	SaleCommon Stock	28,301	$24.82	$702,425.16	Disclosure SEC source: 0000899243-19-022539 · doc4.xml · nonDerivative · entry 2 Scott Randal W · CIK 0001337801 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By OG Family Trust Disclosed balance after: 3,450,669 F1 · kind: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 10, 2018. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $24.61 to $25.00. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.